Menu

New Gene Therapy Shrinks Aggressive Tumors in Mice

Scientists shut down cancer-causing fusion genes with CRISPR.

May 2, 2017
Aggie Mika

 

 

WIKIMEDIA, APERS0N         

                 

A CRISPR-based gene therapy that targets cancerous fusion genes—hybrid genes that are formed when two previously distinct genes join together—shrinks aggressive forms of liver and prostate cancers in mice.

The approach could be developed to address the problem of drug resistance. Cancer cells are prone to evolving new mutations when treated with traditional chemotherapy; using genome editing, the new mutations could be targeted to continue fighting the disease, Jian-Hua Luo, the lead author and a professor of pathology at the University of Pittsburgh School of Medicine, said in a press release.

In the study, published Monday (May 1) in Nature Biotechnology,  Luo and colleagues set their sights on two fusions genes they had previously found to be associated with prostate cancer and various forms of rapid and invasive cancer, including liver tumors. Using a modified CRISPR-Cas9 tool that creates a single- rather than double-stranded break in DNA, they targeted the chromosomal breakpoints that form these fusion genes and replaced fusion DNA with a gene encoding the enzyme HSV1-tk.

This enzyme effectively kills tumor cells by converting the drug ganciclovir into its active form, which then blocks DNA synthesis and leads to cell death. (Ganciclovir is used to treat cytomegalovirus in humans.)

The researchers found that HSV1-tk insertion followed by ganciclovir treatment killed tumors in dishes and shrank them in mice. In mice transplanted with human prostate and liver cancers, this gene therapy also stopped tumors from spreading, and allowed all 17 mice to survive the eight-week study. On the other hand, tumors continued to grow and spread in control mice, and all died before the study ended.

“This is the first time that gene editing has been used to specifically target cancer fusion genes,” said Luo in the statement. “It is really exciting because it lays the groundwork for what could become a totally new approach to treating cancer.” 

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.